Methotrexate for the treatment of rheumatoid arthritis in the biologic era

Still an "anchor" drug?

Ennio Giulio Favalli, Martina Biggioggero, Pier Luigi Meroni

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

The improvement of rheumatoid arthritis (RA) management has been strictly related to methotrexate (MTX) long-term effectiveness, safety profile and its widespread use in clinical practice over the last decades. According to the results of several head-to-head comparative trials against other synthetic DMARDs, MTX has been recognised as the "anchor drug" for the treatment of RA at the end of the 1990s. The subsequent increasing knowledge in the area of RA pathophysiology has progressively expanded the arsenal of available therapeutic tools, especially by the introduction of novel drugs such as biological DMARDs. The introduction of therapies targeted to key molecules and cells involved in RA pathogenesis has significantly changed the strategies for disease management, possibly modifying the key role of MTX. This review first analyses data supporting the evolution of MTX towards the role of "anchor drug" for RA in the pre-biologic era. We will then examine how the introduction and progressive spreading of biological agents could have modified the central role of MTX in the approach to RA.

Original languageEnglish
Pages (from-to)1102-1108
Number of pages7
JournalAutoimmunity Reviews
Volume13
Issue number11
DOIs
Publication statusPublished - Nov 1 2014

Fingerprint

Methotrexate
Rheumatoid Arthritis
Pharmaceutical Preparations
Antirheumatic Agents
Biological Factors
Disease Management
Biological Products
Safety
Therapeutics

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Methotrexate for the treatment of rheumatoid arthritis in the biologic era : Still an "anchor" drug? / Favalli, Ennio Giulio; Biggioggero, Martina; Meroni, Pier Luigi.

In: Autoimmunity Reviews, Vol. 13, No. 11, 01.11.2014, p. 1102-1108.

Research output: Contribution to journalArticle

Favalli, Ennio Giulio ; Biggioggero, Martina ; Meroni, Pier Luigi. / Methotrexate for the treatment of rheumatoid arthritis in the biologic era : Still an "anchor" drug?. In: Autoimmunity Reviews. 2014 ; Vol. 13, No. 11. pp. 1102-1108.
@article{4bf325ff8c2e4c4e87440b933a40a410,
title = "Methotrexate for the treatment of rheumatoid arthritis in the biologic era: Still an {"}anchor{"} drug?",
abstract = "The improvement of rheumatoid arthritis (RA) management has been strictly related to methotrexate (MTX) long-term effectiveness, safety profile and its widespread use in clinical practice over the last decades. According to the results of several head-to-head comparative trials against other synthetic DMARDs, MTX has been recognised as the {"}anchor drug{"} for the treatment of RA at the end of the 1990s. The subsequent increasing knowledge in the area of RA pathophysiology has progressively expanded the arsenal of available therapeutic tools, especially by the introduction of novel drugs such as biological DMARDs. The introduction of therapies targeted to key molecules and cells involved in RA pathogenesis has significantly changed the strategies for disease management, possibly modifying the key role of MTX. This review first analyses data supporting the evolution of MTX towards the role of {"}anchor drug{"} for RA in the pre-biologic era. We will then examine how the introduction and progressive spreading of biological agents could have modified the central role of MTX in the approach to RA.",
author = "Favalli, {Ennio Giulio} and Martina Biggioggero and Meroni, {Pier Luigi}",
year = "2014",
month = "11",
day = "1",
doi = "10.1016/j.autrev.2014.08.026",
language = "English",
volume = "13",
pages = "1102--1108",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "11",

}

TY - JOUR

T1 - Methotrexate for the treatment of rheumatoid arthritis in the biologic era

T2 - Still an "anchor" drug?

AU - Favalli, Ennio Giulio

AU - Biggioggero, Martina

AU - Meroni, Pier Luigi

PY - 2014/11/1

Y1 - 2014/11/1

N2 - The improvement of rheumatoid arthritis (RA) management has been strictly related to methotrexate (MTX) long-term effectiveness, safety profile and its widespread use in clinical practice over the last decades. According to the results of several head-to-head comparative trials against other synthetic DMARDs, MTX has been recognised as the "anchor drug" for the treatment of RA at the end of the 1990s. The subsequent increasing knowledge in the area of RA pathophysiology has progressively expanded the arsenal of available therapeutic tools, especially by the introduction of novel drugs such as biological DMARDs. The introduction of therapies targeted to key molecules and cells involved in RA pathogenesis has significantly changed the strategies for disease management, possibly modifying the key role of MTX. This review first analyses data supporting the evolution of MTX towards the role of "anchor drug" for RA in the pre-biologic era. We will then examine how the introduction and progressive spreading of biological agents could have modified the central role of MTX in the approach to RA.

AB - The improvement of rheumatoid arthritis (RA) management has been strictly related to methotrexate (MTX) long-term effectiveness, safety profile and its widespread use in clinical practice over the last decades. According to the results of several head-to-head comparative trials against other synthetic DMARDs, MTX has been recognised as the "anchor drug" for the treatment of RA at the end of the 1990s. The subsequent increasing knowledge in the area of RA pathophysiology has progressively expanded the arsenal of available therapeutic tools, especially by the introduction of novel drugs such as biological DMARDs. The introduction of therapies targeted to key molecules and cells involved in RA pathogenesis has significantly changed the strategies for disease management, possibly modifying the key role of MTX. This review first analyses data supporting the evolution of MTX towards the role of "anchor drug" for RA in the pre-biologic era. We will then examine how the introduction and progressive spreading of biological agents could have modified the central role of MTX in the approach to RA.

UR - http://www.scopus.com/inward/record.url?scp=84908546592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908546592&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2014.08.026

DO - 10.1016/j.autrev.2014.08.026

M3 - Article

VL - 13

SP - 1102

EP - 1108

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 11

ER -